• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,022
93
67
64
53

COUNTRY

61
13
11
8
6

CATEGORIES

  • 83
  • 122
  • 65
  • 63
  • 37
  • 33
  • 10
  • 10
  • 12
  • 16

PRICE

558
760
1,657
2,771

PUBLISHED

60
218
575
2,771

PRODUCT TYPE

2,658
94
9
6
2
2

Oncology

(2,771 Products)

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition - Product Thumbnail Image

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition In nine best-selling editions, Shara Rosen (MBA, RT), has created authoritative market estimates and forecasted growth models...

August 2014
FROM

Global Breast Cancer Market Report: 2014 Edition

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location....

August 2014
FROM

Advances in the Management of Peritoneal Carcinomatosis

Peritoneal carcinomatosis is a frequent manifestation in the natural history of many gastrointestinal and gynecological cancers. The primary tumors will exfoliate many cancer cells, these cells will...

August 2014

Antiangiogenesis in Cancer Therapy

Angiogenesis is considered one of the hallmarks of cancer. However, barring a few notable examples of significant success such as in clear-cell kidney cancer, angiogenesis inhibition as monotherapy...

August 2014

T-Cell Leukemia - Pipeline Review, H2 2014

T-Cell Leukemia - Pipeline Review, H2 2014 Summary This, ‘T-Cell Leukemia - Pipeline Review, H2 2014’, provides an overview of the T-Cell Leukemia’s therapeutic pipeline. This report provides comprehensive...

July 2014
FROM

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2014

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2014 Summary This, ‘Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2014’, provides an overview of the Metastatic Renal Cell Carcinoma’s...

July 2014
FROM

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014 Summary This, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014’, provides an overview of the Relapsed...

July 2014
FROM

Small-Cell Lung Cancer - Pipeline Review, H2 2014

Small-Cell Lung Cancer - Pipeline Review, H2 2014 Summary This, ‘Small-Cell Lung Cancer - Pipeline Review, H2 2014’, provides an overview of the Small-Cell Lung Cancer’s therapeutic pipeline. This...

July 2014
FROM

Medullary Thyroid Cancer - Pipeline Review, H2 2014

Medullary Thyroid Cancer - Pipeline Review, H2 2014 Summary This, ‘Medullary Thyroid Cancer - Pipeline Review, H2 2014’, provides an overview of the Medullary Thyroid Cancer’s therapeutic pipeline. This...

July 2014
FROM

Medulloblastoma - Pipeline Review, H2 2014

Medulloblastoma - Pipeline Review, H2 2014 Summary This, ‘Medulloblastoma - Pipeline Review, H2 2014’, provides an overview of the Medulloblastoma’s therapeutic pipeline. This report provides comprehensive...

July 2014
FROM

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014 Summary This, ‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014’, provides an overview of the Peripheral T-Cell Lymphomas...

July 2014
FROM

Mantle Cell Lymphoma - Pipeline Review, H2 2014

Mantle Cell Lymphoma - Pipeline Review, H2 2014 Summary This, ‘Mantle Cell Lymphoma - Pipeline Review, H2 2014’, provides an overview of the Mantle Cell Lymphoma’s therapeutic pipeline. This report...

July 2014
FROM

Refractory Multiple Myeloma - Pipeline Review, H2 2014

Refractory Multiple Myeloma - Pipeline Review, H2 2014 Summary This, ‘Refractory Multiple Myeloma - Pipeline Review, H2 2014’, provides an overview of the Refractory Multiple Myeloma’s therapeutic...

July 2014
FROM

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014 Summary This, ‘Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent)...

July 2014
FROM

Metastatic Colorectal Cancer - Pipeline Review, H2 2014

Metastatic Colorectal Cancer - Pipeline Review, H2 2014 Summary This, ‘Metastatic Colorectal Cancer - Pipeline Review, H2 2014’, provides an overview of the Metastatic Colorectal Cancer’s therapeutic...

July 2014
FROM

Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014

Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014 Summary This, ‘Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2014’, provides an overview of the Neuro Endocrine (Carcinoid)...

July 2014
FROM

Rectal Cancer - Pipeline Review, H2 2014

Rectal Cancer - Pipeline Review, H2 2014 Summary This, ‘Rectal Cancer - Pipeline Review, H2 2014’, provides an overview of the Rectal Cancer’s therapeutic pipeline. This report provides comprehensive...

July 2014
FROM

Ewing Sarcoma - Pipeline Review, H2 2014

Ewing Sarcoma - Pipeline Review, H2 2014 Summary This, ‘Ewing Sarcoma - Pipeline Review, H2 2014’, provides an overview of the Ewing Sarcoma’s therapeutic pipeline. This report provides comprehensive...

July 2014
FROM

Metastatic Liver Cancer - Pipeline Review, H2 2014

Metastatic Liver Cancer - Pipeline Review, H2 2014 Summary This, ‘Metastatic Liver Cancer - Pipeline Review, H2 2014’, provides an overview of the Metastatic Liver Cancer’s therapeutic pipeline. This...

July 2014
FROM

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2014

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2014 Summary This, ‘Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2014’, provides an overview of the Opioid-Induced Constipation (OIC)’s...

July 2014
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)